Filing Details
- Accession Number:
- 0001415889-23-016183
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-11 16:20:06
- Reporting Period:
- 2023-12-07
- Accepted Time:
- 2023-12-11 16:20:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1730430 | Kiniksa Pharmaceuticals Ltd. | KNSA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741533 | F. John Paolini | C/O Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton D0 HM 11 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Share | Acquisiton | 2023-12-07 | 28,600 | $1.86 | 73,492 | No | 4 | M | Direct | |
| Class A Common Share | Disposition | 2023-12-07 | 7,380 | $17.54 | 66,112 | No | 4 | S | Direct | |
| Class A Common Share | Disposition | 2023-12-07 | 13,017 | $17.64 | 53,095 | No | 4 | S | Direct | |
| Class A Common Share | Disposition | 2023-12-07 | 6,702 | $17.75 | 46,393 | No | 4 | S | Direct | |
| Class A Common Share | Disposition | 2023-12-07 | 1,501 | $17.81 | 44,892 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Shares | Share Option | Disposition | 2023-12-07 | 28,600 | $0.00 | 28,600 | $1.86 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 111,217 | 2026-09-13 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.595. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.60 to $17.695. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.70 to $17.795. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.80 to $17.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.
Billionaire Hedge Funds
